Topic: antibiotic-resistant bacteria
Motif Bio’s hope of adding to the antibiotic armamentarium for serious bacterial infections has just been dealt a blow by the FDA.
The week’s biotech news included insight into how circulating tumor cells form metastases and how bacteria evade copper antibiotics.
Government officials floated the idea in a report setting out how the U.K. plans to tackle the threat posed by drug-resistant bacteria.
The fund funneled around $16 million (€14 million) into the startups to support research into antibiotics and prophylactic vaccines.
Just over a year after its first-round financing, Locus Bio has signed up J&J as its first big pharma partner, pocketing a $20 million upfront fee.
RedHill Biopharma’s antibiotic cocktail RHB-105 bested an amoxicillin combination in patients with H. pylori infection, topline phase 3 data show.
Roivant has licensed a midstage drug from South Korea’s Intron Bio that it says could be transformative in the fight against resistant bacteria.
Former Bayer VP Alan Westwood has taken the reins of British antimicrobial biotech Matoke Pharma.
Recent biotech developments include improved viral delivery vehicles for gene therapy and compounds that cripple resistant bacteria.